Indole derivatives targeting colchicine binding site as potential anticancer agents

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Pharmacology

Background:

• Microtubules are crucial for cell division and are validated anticancer targets.
• Tubulin protein has distinct binding sites, including the taxane, vinca, and colchicine binding sites (CBS).
• Existing USFDA-approved drugs target microtubules, but no drugs specifically targeting the CBS have reached the market.

Purpose of the Study:

• To review indole derivatives as potential inhibitors of the colchicine binding site (CBS) on tubulin.
• To explore the structure-activity relationships of indole derivatives for potent and selective CBS inhibition.
• To assess the potential of these compounds for developing novel cancer therapies.

Main Methods:

• Literature review of indole derivatives targeting tubulin.
• Analysis of structure-activity relationships (SAR) for CBS binding.
• Examination of molecular docking and competitive binding assay data.

Main Results:

• Indole derivatives demonstrate cytotoxic potential against cancer cells.
• These compounds inhibit cancer cell proliferation, induce apoptosis, and disrupt microtubule formation.
• Binding affinity to the CBS has been confirmed through molecular docking and binding assays.

Conclusions:

• Indole derivatives are promising candidates for targeting the colchicine binding site (CBS).
• SAR studies reveal key features for potent and selective binding to the CBS.
• Further development of indole derivatives could yield effective and less toxic cancer therapies.